Catheter Precision Inc. (VTAK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Catheter Precision Inc. stock (VTAK) is currently trading at $1.20. Catheter Precision Inc. PE ratio is 0.06. Catheter Precision Inc. PS ratio (Price-to-Sales) is 3.88. Analyst consensus price target for VTAK is $2.00. WallStSmart rates VTAK as Sell.
- VTAK PE ratio analysis and historical PE chart
- VTAK PS ratio (Price-to-Sales) history and trend
- VTAK intrinsic value — DCF, Graham Number, EPV models
- VTAK stock price prediction 2025 2026 2027 2028 2029 2030
- VTAK fair value vs current price
- VTAK insider transactions and insider buying
- Is VTAK undervalued or overvalued?
- Catheter Precision Inc. financial analysis — revenue, earnings, cash flow
- VTAK Piotroski F-Score and Altman Z-Score
- VTAK analyst price target and Smart Rating
Catheter Precision Inc.
📊 No data available
Try selecting a different time range
VTAK Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Catheter Precision Inc. (VTAK)
VTAK trades at a significant discount to its Graham intrinsic value of $228.68, offering a 99% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Catheter Precision Inc. (VTAK) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Catheter Precision Inc. (VTAK) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 128.00% year-over-year
Supporting Valuation Data
Catheter Precision Inc. (VTAK) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very low institutional interest at 5.43%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 3.88x sales
Supporting Valuation Data
Catheter Precision Inc. (VTAK) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.42) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 128.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Institutional Own.. Some valuation metrics including Price/Sales (3.88) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -184.50%, Operating Margin at -1339.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -184.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 128.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VTAK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VTAK's Price-to-Sales ratio of 3.88x sits near its historical average of 3.64x (57th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 2% below its historical high of 3.97x set in Mar 2026, and 15% above its historical low of 3.36x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Catheter Precision Inc. (VTAK) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Catheter Precision Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 600,000 with 128% growth year-over-year.
Key Findings
Revenue growing at 128% YoY, reaching 600,000. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 46% of revenue (276,000) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Catheter Precision Inc. maintain 128%+ revenue growth, or will competition slow it down?
Debt management: total debt of 3M is significantly higher than cash (1M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Catheter Precision Inc..
Bottom Line
Catheter Precision Inc. is a high-conviction growth story with revenue accelerating at 128% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:12:55 AM
About Catheter Precision Inc.(VTAK)
NYSE MKT
HEALTHCARE
MEDICAL DEVICES
USA
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.